<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512459</url>
  </required_header>
  <id_info>
    <org_study_id>610/06</org_study_id>
    <nct_id>NCT01512459</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-sequence Two-period, Single Dose Sprinkled on Apple Sauce, Crossover and Relative Bioavailability Study in Healthy Adult, Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the relative bioavailability of Venlafaxine MR
      Capsules 150 mg with Effexor XR Capsules 150 mg under Fed conditions in healthy adult human
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open labeL balanced, randomized, two-treatment. two-period, two-sequence, single
      dose,crossover, evaluation of relative bioavailability of Venlafaxine 150 mg (as the HCl
      salt)MR capsules of Dr. Reddy's comparing with that of Effexor XR (containing Venlafaxine 150
      mg (as the HCl salt)capsules of wyeth Laboratories, Philadelphia, PA, USA in healthy human
      subjects under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>predose, 1.00, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 9.00, 10.00, 12.00, 14.00, 24.00, 36.00, 48.00 and 72.00 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Venlafaxine MR Capsules 150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effexor XR 150 mg Capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Venlafaxine MR Capsules 150 mg</description>
    <arm_group_label>Venlafaxine MR Capsules 150</arm_group_label>
    <arm_group_label>Effexor XR 150 mg Capsules</arm_group_label>
    <other_name>Effexor XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must fulfill all of the following criteria to be considered for inclusion into
        this study:

          -  Subjects who will provide written informed consent.

          -  Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing
             at least 50 kg.

          -  Having a Body mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as
             weight in Kg/height in m2

          -  Subjects must be of normal health as determined by medical history and physical
             examination performed within 21days prior to the commencement of the study.

          -  Subjects whose screening laboratory values are within normal limits or considered by
             the physician/investigator to be of no clinical significance.

          -  Have normal ECG, X-ray and vital signs.

          -  Availability of the subject for the entire study period and willingness to adhere to
             the protocol requirements as evidence by written informed consent.

        Exclusion Criteria:

          -  Subjects incapable of understanding the informed consent.

          -  Subjects who have:

               -  Systolic blood pressure less than 90 mm of Hg and more than 140 .mm of Hg

               -  Diastolic blood pressure less than 60 mm of Hg and more than 94 mm of Hg. Minor
                  deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the
                  physician/investigator.

               -  Pulse rate below 50/min and above 100/min.

          -  History of hypersensitivity or idiosyncratic reaction to Venlafaxine or any other
             related drugs.

          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             .function.

          -  Consumption of grapefruit for the past ten days prior to the dosing day until the
             completion of the study.

          -  Regular smoker who has a habit of smoking more than nine cigarettes per day and has
             difficulty in abstaining from smoking from 48 hours before dosing and until the
             completion of the study.

          -  Subjects who have taken over the counter or prescribed medications for during the last
             7 days from the date of study.

          -  Subjects who have taken enzyme modifying drugs or any systemic medication within the
             past 30 days prior to start of clinical study

          -  History of any psychiatric illness, which may impair the ability to provide written,
             informed consent.

          -  Subjects with clinically significant abnormal values of laboratory parameters.

          -  Subjects who have participated in any other clinical investigation using experimental
             drug or had bled more than 330 mL in the past 90 days before the date of start of
             study.

          -  Subjects with positive screen for drugs of abuse and alcohol.

          -  Any subject in whom Venlafaxine is contraindicated for medical reasons.

          -  Any subject with recent history of surgery

          -  A history of difficulty in donating blood.

          -  A positive test result for HIV antibody and/or syphilis

          -  A recent history of alcoholism (&lt; 2 years) or of moderate (180 ml/day) alcohol use, or
             consumption of alcohol within 48 hr prior to receiving Investigational Product.

          -  Female subjects who are pregnant or who are able (women with child bearing potential)
             to become pregnant during the study will not be allowed to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohanlal Siva Prasad Sayana, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research (P) Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research (P) Ltd</name>
      <address>
        <city>Balanagar</city>
        <state>Hyderabad</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Venlafaxine</keyword>
  <keyword>two way crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

